 | Up a level |
Number of items: 1.
Waldschmidt, D., Merle, P., Granito, A., Huang, Y-H, Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V. V., Gerolami, R., Masi, G., Ross, P. J., Qin, S., Song, T., Bronowicki, J-P, Ollivier-Hourmand, I, Kudo, M., Xu, L., Baumhauer, A., Meinhardt, G., Han, G. and Bruix, J. (2018). Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. Oncol. Res. Treat., 41. S. 281 - 282. BASEL: KARGER. ISSN 2296-5262